

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 7, 2004

MEDICAL DISCOVERIES, INC.

(Exact name of registrant as specified in charter)

<TABLE>
<CAPTION>
<S>

<C>

<C>

UTAH

0-12627

87-0407858

(State or other jurisdiction of
incorporation)

(Commission File Number)

(IRS Employer
Identification No.)

</TABLE>

738 Aspenwood Lane
Twin Falls, Idaho 83301
(208) 736-1799

(Address of Principal Executive Offices and Telephone Number,
Including Area Code)

Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligations of the registrant under any of the
following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act
(17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))

ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT.

On December 7, 2004, Medical Discoveries, Inc. (the "Company") entered into a
Registration Rights Agreement dated December 3, 2004 among Mercator Momentum
Fund, LP; Mercator Momentum Fund III, LP; Mercator Advisory Group, LLC; and the
Company. The Registration Rights Agreement was entered into in connection with
the contingent sale by the Company of 30,000 shares of Series A Convertible
Preferred Stock (the "Preferred Stock") of the Company and warrants to purchase
22,877,478 shares of common stock of the Company to Mercator Momentum Fund, LP;
Mercator Momentum Fund III, LP and Mercator Advisory Group, LLC. The
Registration Rights Agreement requires the Company to file a registration
statement with the Securities and Exchange Commission (the "SEC") registering
the shares of common stock issuable upon conversion of the Preferred Stock and
exercise of the warrants. The registration statement must be filed by December
15, 2004, and the registration statement must be declared effective by the SEC
no later than 90 days after it is filed. A copy of the Registration Rights
Agreement is attached to this report as Exhibit 4.1.

ITEM 3.02 UNREGISTERED SALES OF EQUITY SECURITIES.

The Company has sold the following unregistered securities since October 17,
2004. None of the sales involved an underwriter. The Company believes these
sales were exempt from registration pursuant to Section 4(2) of the Securities
Act of 1933 because the sales did not involve a public offering.

On or about December 7, 2004, the Company entered into a contingent
agreement to sell 30,000 shares of its Preferred Stock and warrants to
purchase 22,877,478 shares of common stock of the Company for a total
offering price of \$3 million. Each share of Preferred Stock entitles the

holder to convert the share of Preferred Stock into the number of shares of common stock resulting from multiplying \$100 by the conversion price. The conversion price is 75% of the average of the lowest three intra-day trading prices for the Company's common stock during the 10 trading days immediately preceding the conversion date, but the conversion price may not exceed \$0.1967. The number of shares of common stock subject to the warrants and the exercise price are subject to equitable adjustment in connection with a stock split, stock dividend or similar transaction. The warrants entitle the holder to purchase up to 22,877,478 shares of common stock of the Company on or before the third anniversary of the issuance date of the warrants at \$0.1967 per share. The number of shares of common stock subject to the warrants and the exercise price are subject to equitable adjustment in connection with a stock split, stock dividend or similar transaction.

The sale is contingent upon the Company entering into and closing a definitive agreement to purchase certain assets in a proposed acquisition, the details of which have not yet been disclosed and regarding which no definitive agreement is yet executed.

-2-

ITEM 7.01 REGULATION FD DISCLOSURE.

On December 7, 2004, the Company released the press release attached to this report as Exhibit 99.1.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

(c) Exhibits.

Exhibit 4.1 Registration Rights Agreement dated December 3, 2004 among Mercator Momentum Fund, LP, Mercator Momentum Fund III, LP, Mercator Advisory Group, LLC and Medical Discoveries, Inc.

Exhibit 99.1 Press release issued December 7, 2004.

-3-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

MEDICAL DISCOVERIES, INC.

/s/ Judy M. Robinett

Judy M. Robinett
President and Chief Executive Officer

Date: December 13, 2004

-4-

INDEX TO EXHIBITS

<TABLE>
<CAPTION>

EXHIBIT NUMBER	DESCRIPTION OF EXHIBIT
4.1	Registration Rights Agreement dated December 3, 2004 among Mercator Momentum Fund, LP, Mercator Momentum Fund III, LP, Mercator Advisory Group, LLC and Medical Discoveries, Inc.
99.1	Press release issued December 7, 2004.

</TABLE>

REGISTRATION RIGHTS AGREEMENT

AGREEMENT dated as of December 3, 2004, between MERCATOR MOMENTUM FUND, LP, and MERCATOR MOMENTUM FUND III, LP. (collectively, the "Fund") and MERCATOR ADVISORY GROUP, LLC ("MAG") (the Fund and MAG are referred to individually as a "Holder" and collectively as the "Holders"), and Medical Discoveries, Inc., a Utah corporation (the "Company").

WHEREAS, the Funds have purchased, for an aggregate of \$3,000,000, an aggregate of 30,000 shares of Series A Convertible Preferred Stock (the "Series A Stock") from the Company, and have the right to cause their Series A Stock to be converted into shares of Common Stock, no par value (the "Common Stock"), of the Company, pursuant to the conversion formula set forth in the Certificate of Determination;

WHEREAS, each of Fund and MAG have acquired Warrants (together, the "Warrants") from the Company, pursuant to which the Holders have the right to purchase in the aggregate up to 22,877,478 shares of the Common Stock through the exercise of the Warrants;

WHEREAS, the Company desires to grant to the Holders the registration rights set forth herein with respect to the shares of Common Stock issuable upon the conversion of the Series A Stock and the exercise of the Warrants.

NOW, THEREFORE, the parties hereto mutually agree as follows:

1. **REGISTRABLE SECURITIES.** As used herein the terms "Registrable Security" means each of the shares of Common Stock (i) issued upon the conversion of the Series A Stock (the "Conversion Shares") or (ii) upon exercise of the Warrants (the "Warrant Shares"), provided, however, that with respect to any particular Registrable Security, such security shall cease to be a Registrable Security when, as of the date of determination that (a) it has been effectively registered under the Securities Act of 1933, as amended (the "Securities Act"), and disposed of pursuant thereto, or (b) registration under the Securities Act is no longer required for the immediate public distribution of such security. The term "Registrable Securities" means any and/or all of the securities falling within the foregoing definition of a "Registrable Security." In the event of any merger, reorganization, consolidation, recapitalization or other change in corporate structure affecting the Common Stock, such adjustment shall be made in the definition of "Registrable Security" as is appropriate in order to prevent any dilution or enlargement of the rights granted pursuant to this Section 1.

2. **REGISTRATION.**

The Company shall file a registration statement (the "Registration Statement") with the Securities and Exchange Commission (the "SEC") on or before December 15, 2004, in order to register the resale of the Registrable Securities under the Securities Act. Once effective, the Company shall maintain the effectiveness of the Registration Statement until the earlier of

-6-

(i) the date that all of the Registrable Securities have been sold, or (ii) the date that the Company receives an opinion of counsel to the Company that all of the Registrable Securities may be freely traded without registration under the Securities Act, under Rule 144 promulgated under the Securities Act or otherwise.

The Company will initially include in the Registration Statement as Registrable Securities Eighty-Two Million Eight Hundred Seventy-Seven Thousand Four Hundred Seventy-Eight (82,877,478) shares of Common Stock issuable upon conversion of the Series A Stock and the maximum number of shares of Common Stock issuable upon exercise of the Warrants.

3. **COVENANTS OF THE COMPANY WITH RESPECT TO REGISTRATION.**

The Company covenants and agrees as follows:

The Company shall use best efforts to cause the Registration Statement to become effective with the SEC as promptly as possible and in no event more than 120 days after the date of this Agreement. If any stop order shall be issued by the SEC in connection therewith, the Company shall use best efforts to obtain promptly the removal of such order. Following the effective date of the Registration Statement, the Company shall, upon the request of any Holder, forthwith supply such reasonable number of copies of the Registration Statement, preliminary prospectus and prospectus meeting the requirements of the Securities

Act, and any other documents necessary or incidental to the public offering of the Registrable Securities, as shall be reasonably requested by the Holder to permit the Holder to make a public distribution of the Holder's Registrable Securities. The obligations of the Company hereunder with respect to the Holder's Registrable Securities are subject to the Holder's furnishing to the Company such appropriate information concerning the Holder, the Holder's Registrable Securities and the terms of the Holder's offering of such Registrable Securities as the Company may reasonably request in writing.

The Company shall pay all costs, fees and expenses in connection with the Registration Statement filed pursuant to Section 2 hereof including, without limitation, the Company's legal and accounting fees, printing expenses, and blue sky fees and expenses; provided, however, that each Holder shall be solely responsible for the fees of any counsel retained by the Holder in connection with such registration and any transfer taxes or underwriting discounts, commissions or fees applicable to the Registrable Securities sold by the Holder pursuant thereto.

The Company will take all actions which may be required to qualify or register the Registrable Securities included in the Registration Statement for the offer and sale under the securities or blue sky laws of such states as are reasonably requested by each Holder of such securities, provided that the Company shall not be obligated to execute or file any general consent to service of process or to qualify as a foreign corporation to do business under the laws of any such jurisdiction.

-7-

4. ADDITIONAL TERMS.

The Company shall indemnify and hold harmless the Holders and each underwriter, within the meaning of the Securities Act, who may purchase from or sell for any Holder, any Registrable Securities, from and against any and all losses, claims, damages and liabilities caused by any untrue statement of a material fact contained in the Registration Statement, any other registration statement filed by the Company under the Securities Act with respect to the registration of the Registrable Securities, any post-effective amendment to such registration statements, or any prospectus included therein or caused by any omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, except insofar as such losses, claims, damages or liabilities are caused by any such untrue statement or omission based upon information furnished or required to be furnished in writing to the Company by the Holders or underwriter expressly for use therein, which indemnification shall include each person, if any, who controls any Holder or underwriter within the meaning of the Securities Act and each officer, director, employee and agent of each Holder and underwriter; provided, however, that the indemnification in this Section 4(a) with respect to any prospectus shall not inure to the benefit of any Holder or underwriter (or to the benefit of any person controlling any Holder or underwriter) on account of any such loss, claim, damage or liability arising from the sale of Registrable Securities by the Holder or underwriter, if a copy of a subsequent prospectus correcting the untrue statement or omission in such earlier prospectus was provided to such Holder or underwriter by the Company prior to the subject sale and the subsequent prospectus was not delivered or sent by the Holder or underwriter to the purchaser prior to such sale and provided further, that the Company shall not be obligated to so indemnify any Holder or any such underwriter or other person referred to above unless the Holder or underwriter or other person, as the case may be, shall at the same time indemnify the Company, its directors, each officer signing the Registration Statement and each person, if any, who controls the Company within the meaning of the Securities Act, from and against any and all losses, claims, damages and liabilities caused by any untrue statement of a material fact contained in the Registration Statement, any registration statement or any prospectus required to be filed or furnished by reason of this Agreement or caused by any omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading, insofar as such losses, claims, damages or liabilities are caused by any untrue statement or omission based upon information furnished in writing to the Company by the Holder or underwriter expressly for use therein.

If for any reason the indemnification provided for in the preceding section is held by a court of competent jurisdiction to be unavailable to an indemnified party with respect to any loss, claim, damage, liability or expense referred to therein, then the indemnifying party, in lieu of indemnifying such indemnified party thereunder, shall contribute to the amount paid or payable by the indemnified party as a result of such loss, claim, damage or liability in such proportion as is appropriate to reflect the relative fault of the indemnified party and the indemnifying party, as well as any other relevant equitable considerations.

Neither the filing of a Registration Statement by the Company pursuant to this Agreement nor the making of any request for prospectuses by the Holder shall impose upon any Holder any obligation to sell the Holder's

With a copy to

Stoel Rives LLP
101 S. Capitol Blvd., Suite 1900
Boise, Idaho 83702
Telephone No.: (208) 389-9000
Facsimile No.: (208) 389-9040
Attention: Stephen R. Drake

All such notices and communications shall be deemed to have been duly given: (i) when delivered by hand, if personally delivered; (ii) five business days after being deposited in the mail, postage prepaid, if mailed certified mail, return receipt requested; (iii) one business day after being timely delivered to a next-day air courier guaranteeing overnight delivery; (iv) the date of transmission if sent via facsimile to the facsimile number as set forth in this Section or the signature page hereof prior to 4:00 p.m. on a business day, or (v) the business day following the date of transmission if sent via facsimile at a facsimile number set forth in this Section or on the signature page hereof after 4:00 p.m. or on a date that is not a business day. Change of a party's address or facsimile number may be designated hereunder by giving notice to all of the other parties hereto in accordance with this Section.

-10-

10. BINDING EFFECT; BENEFITS. Any Holder may assign its rights hereunder. This Agreement shall inure to the benefit of, and be binding upon, the parties hereto and their respective heirs, legal representatives, successors and assigns. Nothing herein contained, express or implied, is intended to confer upon any person other than the parties hereto and their respective heirs, legal representatives and successors, any rights or remedies under or by reason of this Agreement.
11. HEADINGS. The headings contained herein are for the sole purpose of convenience of reference, and shall not in any way limit or affect the meaning or interpretation of any of the terms or provisions of this Agreement.
12. SEVERABILITY. Any provision of this Agreement which is held by a court of competent jurisdiction to be prohibited or unenforceable in any jurisdiction(s) shall be, as to such jurisdiction(s), ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions of this Agreement or affecting the validity or enforceability of such provision in any other jurisdiction.
13. JURISDICTION. Each of the parties irrevocably agrees that any and all suits or proceedings based on or arising under this Agreement may be brought only in and shall be resolved in the federal or state courts located in the City of Los Angeles, California and consents to the jurisdiction of such courts for such purpose. Each of the parties irrevocably waives the defense of an inconvenient forum to the maintenance of such suit or proceeding in any such court. Each of the parties further agrees that service of process upon such party mailed by first class mail to the address set forth in Section 9 shall be deemed in every respect effective service of process upon such party in any such suit or proceeding. Nothing herein shall affect the right of either party to serve process in any other manner permitted by law. Each of the parties agrees that a final non-appealable judgment in any such suit or proceeding shall be conclusive and may be enforced in other jurisdictions by suit on such judgment or in any other lawful manner.
14. ATTORNEYS' FEES AND DISBURSEMENTS. If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party or parties shall be entitled to receive from the other party or parties reasonable attorneys' fees and disbursements in addition to any other relief to which the prevailing party or parties may be entitled.

[The balance of this page is intentionally left blank.]

-11-

the parties hereto as of the date first above written.

MEDICAL DISCOVERIES, INC.

By: _____
Name: Judy M. Robinett
Its: President & CEO

HOLDERS:

MERCATOR MOMENTUM FUND, LP

By: Mercator Advisory Group, LLC
Its: General Partner

By: _____
Name: David Firestone
Its: Managing Member

MERCATOR MOMENTUM FUND III, LP

By: Mercator Advisory Group, LLC
Its: General Partner

By: _____
Name: David Firestone
Its: Managing Member

MERCATOR ADVISORY GROUP, LLC

By: _____
Name: David Firestone
Its: Managing Member

Contact: Medical Discoveries, Inc.
208-736-1799

FOR IMMEDIATE RELEASE

MEDICAL DISCOVERIES INC. SIGNS AGREEMENTS FOR \$3,000,000
EQUITY PRIVATE PLACEMENT

Funds to Support Targeted Acquisition

TWIN FALLS, IDAHO, December 7, 2004 - Medical Discoveries, Inc. (OTC-BB as MLSC) announced today that it has signed agreements for a \$3,000,000 equity private placement consisting of convertible preferred stock and warrants. The financing is structured to support the prospective acquisition of certain biotechnology assets and intellectual property that the Company is currently pursuing.

The Equity Private Placement was made by Mercator Advisory Group, LLC of Los Angeles, California, through its designated funds, Mercator Momentum Fund, LP. and Mercator Momentum Fund III, LP.

Ascendant Securities LLC of Irvine, California served as placement agent on the transaction.

Pursuant to the terms of the equity financing, the funding is contingent upon the Company closing the acquisition of certain intellectual property from a biotechnology company. The Company has executed a letter of intent with the selling company, but has not yet reached a definitive agreement. Therefore, there can be no assurances that the acquisition will close or that the investment will be completed. The Company anticipates that 100% of the proceeds of the investment will be used for the acquisition and related costs.

Additional information regarding the financing and prospective acquisition may be found in the Company's 8-K filing anticipated later this week. Details regarding the specifics of the prospective acquisition will be withheld due to confidentiality until definitive documentation is executed.

Formed in 1991, Medical Discoveries, Inc. is a publicly traded (OTC Bulletin Board as MLSC) development-stage biopharmaceutical research company engaged in the research, development and validation of its patented anti-infective technology. MDI's electrolyzed solution of free radicals represents a novel approach to treating its initial target indications, Cystic Fibrosis and HIV.

Information in this press release relating to the potential of MDI constitutes forward-looking statements. Actual results in future periods may differ materially from the forward-looking statements because of a number of risks and uncertainties set forth in MDI's 2003 Annual Report on Form 10-KSB, as amended, and other filings with the Securities and Exchange Commission.

###